Racura Oncology has secured $34.3 million following a series of fundraising initiatives supported by new and existing shareholders, giving the company a strong cash balance to fully fund its RC220 clinical programs in Acute Myeloid Leukaemia, EGFRm non-small cell lung cancer and anthracycline cardioprotection in solid tumour patients. …
Racura completes significant fund raise to advance three clinical trials
June 17, 2026 Australian Biotech
Latest Video
New Stories
-
Australians want more from healthcare as convenience, prevention and fragmentation reshape care
June 18, 2026 - - Latest News -
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 - - Latest News -
Is China's international benchmarking a bigger short-term risk to medicines access?
June 18, 2026 - - Latest News -
Neurizon secures GMP supply of monepantel to strengthen NUZ 001 commercial readiness
June 17, 2026 - - Australian Biotech -
Percheron completes HMBD-002 drug substance manufacture
June 17, 2026 - - Australian Biotech -
Racura completes significant fund raise to advance three clinical trials
June 17, 2026 - - Australian Biotech -
Novartis names interim leader for Australia and NZ after Country President departs
June 17, 2026 - - Latest News